Allergy Therapeutics (LSE:AGY) — Market Cap & Net Worth
Market Cap & Net Worth: Allergy Therapeutics (AGY)
Allergy Therapeutics (LSE:AGY) has a market capitalization of $5.23 Million (GBX42.99 Billion) as of June 22, 2026. Listed on the LSE stock exchange, this UK-based company holds position #28458 globally and #464 in its home market, demonstrating a -12.50% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Allergy Therapeutics's stock price GBX7.00 by its total outstanding shares 6141439951 (6.14 Billion). Review how much debt does Allergy Therapeutics carry to assess the company's total debt and financial obligations.
Allergy Therapeutics Market Cap History: 2015 to 2026
Allergy Therapeutics's market capitalization history from 2015 to 2026. Data shows change from $22.04 Million to $5.23 Million (-12.29% CAGR).
Index Memberships
Allergy Therapeutics is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE AIM All Share Index
FTAI
|
$937.70 Million | 0.56% | #36 of 722 |
Weight: Allergy Therapeutics's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Allergy Therapeutics Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Allergy Therapeutics's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.15x
Allergy Therapeutics's market cap is 0.15 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $15.60 Million | $48.51 Million | -$13.07 Million | 0.32x | N/A |
| 2017 | $21.30 Million | $64.14 Million | -$2.48 Million | 0.33x | N/A |
| 2018 | $10.18 Million | $68.35 Million | -$7.53 Million | 0.15x | N/A |
| 2019 | $7.66 Million | $73.72 Million | $3.47 Million | 0.10x | 2.21x |
| 2020 | $12.42 Million | $78.20 Million | $7.06 Million | 0.16x | 1.76x |
| 2021 | $24.66 Million | $84.33 Million | $2.89 Million | 0.29x | 8.54x |
| 2022 | $4.67 Million | $72.77 Million | -$13.78 Million | 0.06x | N/A |
| 2023 | $1.87 Million | $59.59 Million | -$43.07 Million | 0.03x | N/A |
| 2024 | $4.86 Million | $55.20 Million | -$40.22 Million | 0.09x | N/A |
| 2025 | $8.22 Million | $55.04 Million | -$40.13 Million | 0.15x | N/A |
Competitor Companies of AGY by Market Capitalization
Companies near Allergy Therapeutics in the global market cap rankings as of June 22, 2026.
Key companies related to Allergy Therapeutics by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #515 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #554 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #602 globally with a market cap of $45.20 Billion USD ( CN¥308.87 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #627 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #515 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #554 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $42.94 |
| #602 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.20 Billion | CN¥48.42 |
| #627 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.50 |
Allergy Therapeutics Historical Marketcap From 2015 to 2026
Between 2015 and today, Allergy Therapeutics's market cap moved from $22.04 Million to $ 5.23 Million, with a yearly change of -12.29%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX5.23 Million | -36.36% |
| 2025 | GBX8.22 Million | +69.23% |
| 2024 | GBX4.86 Million | +160.00% |
| 2023 | GBX1.87 Million | -60.00% |
| 2022 | GBX4.67 Million | -81.06% |
| 2021 | GBX24.66 Million | +98.50% |
| 2020 | GBX12.42 Million | +62.20% |
| 2019 | GBX7.66 Million | -24.77% |
| 2018 | GBX10.18 Million | -52.19% |
| 2017 | GBX21.30 Million | +36.53% |
| 2016 | GBX15.60 Million | -29.24% |
| 2015 | GBX22.04 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 22nd, 2026 the market cap of Allergy Therapeutics was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.23 Million USD |
| MoneyControl | $5.23 Million USD |
| MarketWatch | $5.23 Million USD |
| marketcap.company | $5.23 Million USD |
| Reuters | $5.23 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Allergy Therapeutics
Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as wel… Read more